Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501951 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2TDP1HMGCRCHRM1 | |
| SCHEMBL8727012 | 0.79 | HMGCR (0.48) | ALDH1A1TDP1HMGCRCHRM1TBXA2R | |
| SCHEMBL27824795 | 0.77 | KDM4E (0.30) | — | |
| SCHEMBL22455355 | 0.77 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2TDP1 | |
| Ammonia Solution, Strong SCHEMBL25278018 | 0.75 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL21135945 | 0.75 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL8466940 | 0.72 | TET2 (0.52) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL13636130 | 0.71 | CA5A (0.31) | — | |
| SCHEMBL17480197 | 0.71 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL3112492 | 0.70 | TDP1 (0.33) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017121850-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | NOVO NORDISK A/S (DK) | 2017-07-20 | — | — | WO | disclosed |
| US-20120029197-A1 | Method for Preparing Sulfur-Containing Compounds | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2012-02-02 | — | — | US | disclosed |
| US-20120029197-A1 | Method for Preparing Sulfur-Containing Compounds | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2012-02-02 | — | — | US | disclosed |
| WO-2010066450-A1 | A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196456-A1 | A method for preparing sulfur-containing compounds | Royal College of Surgeons in Ireland (IE) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029197-A1 | Method for Preparing Sulfur-Containing Compounds | SULT1E1, SULT1A1, TST | ALDH1A1 195/4885SMN1; SMN2 1103/4885TDP1 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.